Biotech IPO “Class of 2010” Continues to Impress

Posted May 18th, 2011 in Exits IPOs M&As

Matt Herper over at FORBES suggested I update and repost the “Glimmer of Hope” “Class of 2010″ biotech IPOs blog post, which I’ve now done, and the performance continues to impress:

The average and median performance of this “Class” is 33% and 21%, respectively – which is markedly better than all the recent prior classes’ performance.  Ventrus, Aegerion, AVEO, Complete Genomics, and Trius have all appreciated by more than 50% since their IPO.

Pretty impressive returns for the top half the group.   I’m still skeptical about most new IPOs, but much of this group certainly seems to be performing well.

This entry was posted in Exits IPOs M&As. Bookmark the permalink.